This is the most important conclusion drawn from the post-hoc analysis of the MOVES clinical trial which was presented today at the annual meeting of the American Academy of Rheumatology.
Bioiberica was an exhibitor at the Supplyside West fair (19 to 22 October in Las Vegas).
Osteoarthritis (OA) affects more than seven million adult Spaniards and costs 4,700 million per year. Of those, 46 percent correspond to healthcare assistance, 22 percent to lost work, 13 percent to hospital admissions, 7 percent to diagnostic tests and 5 percent to drugs.
Osteoarthritis is a chronic joint disease that may cause or worsen other conditions, such as hypertension, obesity or diabetes.